Cellectar Biosciences, Inc.
CLRB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001279704
No open-market purchases or sales by Cellectar Biosciences, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $9.69M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +10 vs. previous quarter
- 29
- 13F valueReported value at the end of Q2 2026
- $9.69M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding CLRB, Q2 2026
No superinvestor reported holding CLRB at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Cellectar Biosciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 11, 2026 (view filing)8:07 PM ET | May 7 | 4 days | Longcor JarrodChief Operating Officer | PPurchase | +8.68K | $2.88 | +$25.0K | +73.7%20.5K after | |
| May 11, 2026 (view filing)8:07 PM ET | May 7 | 4 days | Longcor JarrodChief Operating Officer | PPurchase | +26.0K | $0.01 | +$260.4 | –36.1K after | Derivative |
| May 11, 2026 (view filing)8:05 PM ET | May 7 | 4 days | Caruso James VChief Executive Officer | PPurchase | +8.68K | $2.88 | +$25.0K | +74.6%20.3K after | |
| May 11, 2026 (view filing)8:05 PM ET | May 7 | 4 days | Caruso James VChief Executive Officer | PPurchase | +26.0K | $0.01 | +$260.4 | –36.1K after | Derivative |
| Dec 16, 2025 (view filing) | Dec 12 | 4 days | Neis JohnDirector | SSale | −198 | $3.70 | −$732.6 | −95.2%10 after | |
| Jul 3, 2025 (view filing)8:02 AM ET | Jul 2 | 1 day | Caruso James VChief Executive Officer | PPurchase | +10.0K | $4.99 | +$49.9K | +610.5%11.6K after | |
| Jul 3, 2025 (view filing)8:02 AM ET | Jul 2 | 1 day | Caruso James VChief Executive Officer | PPurchase | +10.0K | $0.01 | +$100 | –10.0K after | Derivative |
| Jul 3, 2025 (view filing)8:01 AM ET | Jul 2 | 1 day | Longcor JarrodChief Operating Officer | PPurchase | +10.0K | $4.99 | +$49.9K | +361.3%12.8K after | |
| Jul 3, 2025 (view filing)8:01 AM ET | Jul 2 | 1 day | Longcor JarrodChief Operating Officer | PPurchase | +10.0K | $0.01 | +$100 | –10.0K after | Derivative |
| Jul 3, 2025 (view filing)8:00 AM ET | Jul 2 | 1 day | Kolean Chad JChief Financial Officer | PPurchase | +5.00K | $4.99 | +$24.9K | +352.6%6.42K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Cellectar Biosciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Caligan Partners LP | 469,998 | $1.31M | 0.06% | +469,998 | New |
| Nantahala Capital Management, LLC | 439,996 | $1.22M | 0.04% | +439,996 | New |
| StemPoint Capital LP | 354,938 | $986.7K | 0.17% | +354,938 | New |
| Vanguard Capital Management LLC | 327,367 | $910.1K | 0.00% | +245,483+299.8% | Added |
| Silverarc Capital Management, LLC | 321,728 | $894.4K | 0.10% | +321,728 | New |
| Bleichroeder LP | 288,679 | $802.5K | 0.14% | +188,679+188.7% | Added |
| Jupiter Topco LLC | 274,156 | $759.4K | 0.00% | +274,156 | New |
| Balyasny Asset Management LLC | 220,000 | $611.6K | 0.00% | +220,000 | New |
| Empery Asset Management, LP | 189,605 | $527.1K | 0.61% | +189,605 | New |
| Diadema Partners LP | 138,341 | $384.6K | 0.14% | +138,341 | New |